ct-95
·Code: LNK-101
ct-95: developed by 1 company · 1 clinical trial tracked.
ct-95 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ct-95 to CNTX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ct-95 → CNTX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Context Therapeutics Inc. (CNTX) Mesothelin-Expressing Tumors | Phase 1 |
Clinical Trials (1)
Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression
Primary endpoint: Determine the MTD or RD of CT-95 [Safety and Tolerability]
Interventionalopen70 targetStarted 2025-03Completion 2028-129 sites · United StatesContext Therapeutics Inc.
Frequently asked questions
Who is developing ct-95?
ct-95 is being developed by Context Therapeutics Inc..
How many clinical trials involve ct-95?
BioSniper tracks 1 clinical trial involving ct-95.